The company cites diagnostics momentum and AI-driven demand as key drivers for its 2026 financial outlook.
Revvity projected organic growth of 4% to 5% and adjusted earnings per share of $5.30 to $5.40 for Q2 2026. The forecast reflects strong diagnostics performance and rising demand tied to AI applications in its sector.
In the second quarter, the company reported 3% pro forma organic growth, exceeding its revenue expectations. Management attributed the results to robust demand in its core markets, particularly in diagnostics and technology-driven solutions.
The outlook aligns with broader industry trends, where AI integration is increasingly influencing growth trajectories in life sciences and diagnostics.